Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 7, 2005, Pages 867-872

  Islam, Sara ^a   Antonsson, Linda ^a   Westin, Johan ^a   Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Biomarkers; Cirrhosis; Fibrosis; Hepatitis C; Serum

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PLATELET COUNT; PROGNOSIS; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 22144498854     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520510015674     Document Type: Article

References (21)

1. WHO. Hepatitis C global prevalence (update). Weekly Epidemiologi Record 1999;74:425-7.
2. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000;31:1014-8.
3. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
4. Garcia G, Keeffe EB. Liver biopsy in chronic hepatitis C: routine or selective. Am J Gastroenterol 2001;96:3053-5.
5. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357(9262):1069-75.
6. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003;98:1150-4.
7. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003;18:253-7.
8. Carrera G, Paternain JL, Carrere N, Folch J, Courtade-Saidi M, Orfila C, et al. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment. Am J Gastroenterol 2003;98: 1142-9.
9. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
10. Kaul V, Friedenberg FK, Braitman LE, Anis U, Zaeri N, Fazili J, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002;97:2623-8.
11. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
12. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33.
13. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:2419-25.
14. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.
15. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
17. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-9.
18. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43:2156-9.
19. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002;37:572-7.
20. Coverdale SA, Samarasinghe DA, Lin R, Kench J, Byth K, Khan MH, et al. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. Am J Gastroenterol 2003;98:1384-90.
21. Mangia A, Minerva N, Ricci GL, Romano M, Canetta V, Persico M, et al. HCV genotype 2 and 3 can be cured by PEG-IFN-ALFA-2B and RBV for 12 wks: a randomized controlled study. J Hepatol 2004;40 Suppl 1:34.